Curtis Law Group Announces Reglan Mass Tort Settlements

USA - English

• USA - English

Dallas, Texas (PRWEB) September 30, 2014 -- Curtis Law Group (http://www.curtis-lawgroup.com) announces that a proposed nationwide settlement has been reached with one of the manufacturers of the drug called Reglan (Metoclopramide). The financial terms of the proposed settlement of cases filed against Generics International (US Parent) Inc. remain confidential, pending approval by a substantial number of the affected consumers of the drug. In re: Reglan/Metoclopramide Litigation, JCCP 4631, Superior Court, State of California, San Francisco County.

Reglan (Metoclopramide) was a drug first marketed in the 1980’s, and was often used for treatment of acid reflux, GERD and other gastrointestinal disorders. By the mid-1980’s, the product was sold generically by numerous manufacturers. During the years the product has been on the market, studies have connected the drug to a permanent and debilitating movement disorder, tardive dyskinesia.** Consumers injured by this product suffer from involuntary movements- such as facial distortions, grimacing, tongue thrusting and involuntary movements of many other parts of their bodies.* The condition is permanent, life altering and treatments are extremely limited and often dangerous.*

Lawsuits against the manufacturers of the drug have been filed nationwide, and the number of filed cases multiplied exponentially after the FDA demanded that a black box warning be added to the drug label in 2009. Approximately 4,500 cases are believed to be pending around the country against a number of different manufacturers of the drug. Most of the cases have been consolidated into state courts in California, Pennsylvania and New Jersey. In re: Reglan/Metoclopramide Litigation, Pennsylvania Court of Common Pleas, Philadelphia County and In re: Reglan Litigation, Case No. 289, Superior Court of New Jersey, Atlantic County.

Curtis Law Group represents hundreds of these clients nationwide. Today’s announcement is the first step in trying to settle all of the cases currently pending against Generics International. Details of the proposal will be shared with the plaintiffs who have already filed suit against Generics International, and the nationwide settlement will depend on approval of those parties. It is estimated that the settlement could involve as many as 1,000 plaintiffs.

Curtis Law Group (http://www.curtis-lawgroup.com) is a nationally recognized leader in pharmaceutical litigation. With more than two decades of successful litigation across the nation, Curtis Law Group is proud to represent victims of dangerous drugs, defective medical devices and those who have suffered a catastrophic injury or loss due to the negligence of others. Founder Bill Curtis is board certified in personal injury trial law by the Texas Board of Legal Specialization, has been named a Texas Super Lawyer for more than 10 years and holds the highest rating from his peers through Martindale-Hubble.

• http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm149533.htm
• Daniel D. Sewell, MD, Dilip V. Jeste, MD. "Metoclopramide-Associate Tardive Dyskinesia." Archives of Family Medicine Volume 1. (1992): 271-278. Print.
• http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/017854s058lbl.pdf
• Linda Ganzini, MD; Daniel E. Casey, MD; William F. Huffman, PhD, MD; Anthony L. McCall, MD, PhD. "The Prevalence of Metoclopramide-Induced Tardive Dyskinesia and Acute Extrapyrmidal Movement Disorders." Archive of Internal Medicine Volume 153. (1993): 1469-1475. Print.

Contact info:

William B. Curtis
7557 Rambler Road, Suite 1050
Dallas, Texas 75231
214/890-1000
214/890-1010 fax
http://www.Curtis-LawGroup.com
[email protected]

William B. Curtis, Curtis Law Group, http://www.curtis-lawgroup.com/, +1 2148901000, [email protected]